Tender detail
Open-house medicine rebate agreements for indacaterol and mometasone, ATC R03AK14
Summary
The procurement concerns non-exclusive rebate agreements for medicines containing the active ingredients indacaterol and mometasone (ATC R03AK14). Agreements may be concluded at any time during the period from 1 December 2026 to 30 November 2028. Medicines included on the BfArM list of paediatric medicines under Section 35(5a) SGB V are excluded.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.